Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Healthy
Interventions: Safety tested norovirus inoculum; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 99 Years
Enrollment: 517 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Conditions: Vaccine Reaction
Interventions: MicronJet, Fluzone® Quadrivalent, Fluzone® High Dose Quadrivalent; Device · Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel; Diagnostic Test
Lead sponsor: Thermo Fisher Scientific, Inc; Industry
Eligibility: Not listed
Enrollment: 1,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: San Diego, California • Lake City, Florida • Miami, Florida + 13 more

Conditions: Influenza
Interventions: FluBlok, Fluzone, FluCelVax, Fluzone HD; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 49 Years
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Immunologic Tests
Interventions: Serum samples; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 64 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute, Uncomplicated Human Influenza
Interventions: Peramivir, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more

Conditions: Influenza
Interventions: CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more

Conditions: Leukemia
Interventions: Campath, Fludarabine, Total Body Irradiation (TBI), T-Cell Deplete; Drug · Radiation · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 4 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Influenza,Human, COVID-19
Interventions: Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo; Biological · Combination Product · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Influenza, Human
Interventions: oseltamivir, placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 60
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more

Conditions: Influenza
Interventions: Ear Loop Procedure Mask, 62% Ethyl Alcohol Hand Sanitizer; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
Interventions: Not listed
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: Not listed
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Mucosal Immunity
Interventions: Fluzone; Drug
Lead sponsor: John Sundy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cancer, Influenza Viral Infections
Interventions: Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine; Biological
Lead sponsor: Saad Jamshed MD; Other
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Influenza, Gammopathy
Interventions: Fluzone; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: Flumist Quadrivalent Nasal Product; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 49 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: Seasonal Influenza DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Fluzone IN; Biological
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza, Human
Interventions: NanoFlu, Fluzone Quadrivalent; Biological
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 2,654 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more

Search by objective public record fields.

Infectivity of Norovirus in Groundwater-Human Challenge Study

H5N1 (Clade 2) Vaccination of Adults and Elderly

Intradermal Influenza Vaccination

Project STARFISH - PRJ0002679

Comparison of Three Licensed Influenza Vaccines

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission

Idylla IFV-RSV Panel Clinical Testing

Strategies for Enhancing Mucosal Immunity to Influenza Vaccine

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults